share_log

Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health首席执行官和特别嘉宾加入Radius Research公司进行投资者更新
GlobeNewswire ·  2022/01/25 08:11

VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "AVCR") is excited to be joined by Shoppers Drug Mart Pharmacist and Associate Owner, Mohamad Adel Elsabakhawi and Abbott Rapid Diagnostics' General Manager Daniel St. Pierre and National Sales Manager, Soul Khan. 

温哥华,不列颠哥伦比亚省,2022年1月25日(环球通讯社)AVRICORE Health Inc.(TSXV:AVCR)(“公司“或”AVCR)很高兴有购物者药剂师兼副店主穆罕默德·阿德尔·埃尔萨巴哈维和雅培快速诊断公司的总经理丹尼尔·圣皮埃尔和苏尔汗的全国销售经理加盟。

"The Company enjoyed an incredible year in 2021, and throughout the Holidays and the beginning of the New Year, we have continued to finalize key agreements which will lead to substantial growth this year." said Avricore Health CEO, Hector Bremner. "Our partners are as excited as we are and we look forward to deepening our collaboration." 

公司在2021年经历了令人难以置信的一年,在整个假期和新年伊始,我们继续敲定关键协议,这些协议将导致今年的大幅增长。“Avricore Health首席执行官赫克托·布雷姆纳(Hector Bremner)说。我们的合作伙伴和我们一样兴奋,我们期待着深化我们的合作。“

Call Details: 

通话详细信息:

January 25th, 2022 @ 1:15pm PT / 4:15pm ET via Zoom 
Register here:  

2022年1月25日,太平洋时间下午1:15,东部时间下午4:15,通过Zoom
请在此处注册:

Agenda:
The 60-minute call agenda will be as follows:
10min: Opening Remarks / Team Introductions
20Min: Overview Presentation and Update
30Min: Q&A

议程:
60分钟的电话会议议程如下:
10分钟:开场白/团队介绍
20分钟:概述演示文稿和更新
30分钟:问答

We're looking forward to seeing you there, please review our most recent investor presentation here: 

我们期待着在那里与您见面,请在此处查看我们最新的投资者演示文稿:

About HealthTab™

关于HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

HealthTab™是一款交钥匙医疗设备测试解决方案,它将同类最佳的医疗设备技术与基于云的安全平台相结合,用于解决紧迫的全球健康问题。只需手指扎出几滴血,该系统就能在现场生成实验室准确的结果,并实时报告数据。测试菜单包括多达23个用于筛选和管理慢性疾病的关键生物标记物,如糖尿病和心脏病(例如,HbA1c、血脂分布、EGFR)。HealthTab™最近还增加了细菌和病毒检测功能,如链球菌和新冠肺炎。
HealthTab™网络模型与当今药剂业的任何模式都不同。它使知识渊博和值得信赖的药剂师在初级保健服务中发挥更大的作用,同时使患者能够更好地控制自己的健康。它还减少了成本和等待时间,并提供了许多潜在的收入来源,包括设备租赁和耗材、直接访问测试、疾病预防和管理计划、赞助健康计划、分散临床试验、真实世界数据(RWD)集,以及通过API集成第三方应用程序。

About Avricore Health Inc.

关于Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc.(多伦多证券交易所股票代码:AVCR)是一家药房服务创新者,专注于获取和开发旨在推动药房向前发展的早期技术。通过其全资子公司HealthTab™的旗舰产品,该公司的使命是通过在社区药店创建世界上最大的快速检测设备网络,使每个人都更容易获得可操作的健康信息。

Contact:

联系人:

Avricore Health Inc.                                        
Hector Bremner, CEO 604-773-8943         
info@avricorehealth.com                                         
                                 

Avricore Health Inc.
首席执行官赫克托·布雷姆纳(Hector Bremner),电话:604-773-8943
邮箱:info@avricoreHealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

有关前瞻性陈述的注意事项
本新闻稿中涉及Avricore Health对未来的预期、计划、意图或战略的信息均为前瞻性陈述,不是事实,涉及许多风险和不确定性。Avricore Health通常使用诸如“展望”、“将会”、“可能”、“可能”、“仍然”、“将要”、“计划”、“相信”、“可能”、“预期”、“打算”、“预期”、“估计”、“未来”、“定位”、“潜在”、“项目”、“保持”、“预定”、“设置为“受制于”、“即将到来”以及类似的表达方式,以帮助识别前瞻性陈述。在本新闻稿中,前瞻性陈述包括有关以下方面的陈述:配售完成及其预期时间和公司预期配售收益的使用;HealthTab™平台向药剂师和患者提供的独特功能。前瞻性陈述反映了当时对Avricore Health管理层的预期、信念、假设、估计和预测。本新闻稿中的前瞻性陈述基于截至本新闻稿发布之日Avricore Health可获得的信息。前瞻性陈述在作出时被认为是真实的,但最终可能被证明是不正确的。这些陈述不是对Avricore Health公司未来业绩的保证,会受到一些风险、不确定因素和其他因素的影响,其中一些风险、不确定因素和其他因素是Avricore Health公司无法控制的,可能导致实际结果与目前的预期大不相同,包括但不限于:未能满足监管要求;市场变化;经济状况的潜在下滑;以及Avricore公司公开申报文件中描述的其他风险因素。这些前瞻性陈述仅说明截止日期。, 除非法律另有要求,否则公司没有义务公开更新这些信息,以反映新的信息或未来事件或情况的发生。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this statement.

多伦多证券交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本声明的充分性或准确性承担责任。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发